11β-HSDs predict steroid sensitivity in nephrotic synd.
ABSTRACT
Childhood nephrotic syndrome (NS), in which steroid-dependence occurs concurrently with steroid-resistance, requires aggressive therapy to prevent relapse. Predictive biomarkers that can be used to stratify treatment are urgently needed. Here we report that reciprocal regulation of the glucocorticoid metabolizing enzymes, 11β-hydroxysteroid dehydrogenase (11β-HSD) types 1 and 2 is associated with steroid-responsiveness and disease remission in childhood NS, potentially providing a marker to identify patients in which aggressive therapy is required.
Synthetic glucocorticoids (GCs) are used as the first-line treatment for childhood idiopathic nephrotic syndrome (NS). The initial response to steroids is a major prognostic factor in childhood NS. 1 More than 90% of children with minimal change nephrotic syndrome (MCNS) achieve initial remission after an 8-week course of prednisolone on the International
Study of Kidney Disease in Children (ISKDC) protocol. 2 However around 60% of steroidresponsive patients experience frequent relapses with some becoming dependent on steroids to prevent further relapse, but requiring higher doses to do so (exhibiting relative resistance to steroids). 2 The mechanisms underlying the development of steroid resistance remain unclear and there are currently no reliable biomarkers to identify patients who will go on to develop steroid dependence and resistance. A recent report suggests that low levels of glucocorticoid receptor (GR) in peripheral blood mononuclear cells (PBMCs) are associated with GC resistance in childhood NS. 3 However, the density and binding affinity of GRs, as determined by dexamethasone binding assays in PBMCs, were not different in children with steroid sensitive and resistant NS. 4 Thus, whether GR in PBMCs are a useful biomarker in NS is unclear. We have previously shown that both the type 1 and type 2 isozymes of the prereceptor GC metabolizing enzyme, 11β-hydroxysteroid dehydrogenase (11β-HSD1 and 11β-HSD2, respectively) are associated with steroid sensitivity in childhood acute lymphoblastic leukemia and indeed, that 11β-HSD2 may contribute to steroid resistance. 5,6 Therefore, we hypothesized that 11β-HSDs in PBMCs could be associated with steroid responsiveness in childhood NS.
CASES AND METHODS
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The American Academy of Pediatrics, 141 Northwest Point Blvd., Elk Grove Village, IL 60007 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 between early and late responders, we determined clinical GC-sensitivity/resistance from the initial response to prednisolone treatment at 2 weeks. This is earlier than the common definition (at 4 weeks), but in concordance with a recent report suggesting that the initial response to steroids (at 7 days) is a major prognostic factor in idiopathic NS. 1 Therefore patients 1, 3 and 4, who showed complete resolution of proteinuria (urine protein/creatinine ratio less than 0.2) at 2 weeks and remained negative until 4 weeks, were classified as GCsensitive. Patient 8 was classified as GC-resistant as she failed to respond to the initial prednisolone treatment. Her histological finding revealed focal segmental glomerulosclerosis on renal biopsy (Table 1) .
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Of the four relapsing nephrotic syndrome patients, one was classified as infrequent relapse (patient 7). The remaining three (patients 2, 5 and 6) were frequent relapsing nephrotic syndrome patients (FRNS). Modified induction therapy was initiated according to our regional protocol (Nagoya City Kidney Disease Study Group). 7 According to this protocol, if FRNS patients are not prescribed prednisolone before relapse, to reduce steroid toxicity, 1 mg/kg dose of prednisolone (maximum dose of 30 mg/m 2 /day) is administered initially, which is lower than the common protocol. Patients already undergoing treatment with ≥1 
RESULTS AND DISCUSSION
HSD11B1, HSD11B2 and NR3C1 mRNA were expressed in PBMC in all cases. Absolute levels varied between patients, so findings are expressed as fold induction following dexamethasone. HSD11B1 mRNA levels were decreased following in vitro dexamethasone treatment of PBMC collected from all patients, before or following prednisolone treatment ( Fig 1A) . The decrease in HSD11B1 mRNA levels following dexamethasone tended to be lower in GC-resistant than in GC-sensitive NS, although this did not achieve significance ( Fig 1A) . In contrast, HSD11B2 mRNA levels were unchanged by dexamethasone treatment of PBMC collected from GC-sensitive NS patients either prior to or following their prednisolone treatment (the fold induction was not significantly different to 1) ( Fig 1B) .
However, HSD11B2 mRNA levels were significantly increased by dexamethasone treatment of PBMC collected from GC-resistant NS patients both prior to, and following, their prednisolone therapy at 2 weeks ( Fig 1B) . The different responses of HSD11B1 and HSD11B2 mRNAs following in vitro dexamethasone revealed a qualitative difference between GC-sensitive and resistant NS, as seen in GC-sensitive and resistant childhood lymphoblastic leukemia. 5 The patterns of HSD11B1 and 2 remained similar during the course of prednisolone therapy, suggesting that GC-sensitivity/resistance is intrinsic in childhood NS.
Levels of NR3C1 mRNA, encoding GR, were unaffected by in vitro treatment of PBMC with dexamethasone ( Fig 1C) .
Expression of 11β-HSD1 and 11β-HSD2 is normally reciprocally regulated. 8 In vivo, 11β-HSD1 predominantly activates endogenous glucocorticoids (converting cortisone to cortisol) whereas 11β-HSD2 catalyses the reverse reaction, inactivating glucocorticoids. However, it should be noted that 11β-HSD2 is a high affinity though low capacity enzyme and thus high levels of glucocorticoids can escape inactivation. 8 The 11β-HSD enzymes potently modulate exogenous GC action as well. They interconvert prednisolone (active) and prednisone (inert), which itself does not bind to GR. 8 In many tissues, there is a switch from 11β-HSD2 to 11β-HSD1 expression as cells differentiate and mature. 9,10 The precise mechanism of this reciprocal regulation remains largely unknown, but transcriptional regulator CAAT/enhancerbinding proteins (C/EBPs) are likely involved, as we have previously shown that they regulate 11β-HSDs in a variety of cell types.
11,12
In normal PBMCs, 11β-HSD1 expression is low and 11β-HSD2, negligible. 8 However in inactivation. Therefore we suggest that dexamethasone should be used to treat this condition, rather than prednisolone. The present study has some limitations. We evaluated only Japanese NS patients at our hospital, who may not be representative of childhood idiopathic NS patients in other ethnic groups. Frequent relapse patients were treated with a lower dose of prednisolone (1 mg/kg/day), according to our regional protocol which is intended to reduce steroid toxicity. 7 Moreover, the sample size is small, and statistical significance was not achieved for the HSD11B1 mRNA findings. Therefore our findings are preliminary, qualitative rather than quantitative, and require confirmation in a larger number of patients.
Nevertheless, they suggest that analysis of expression of these isozymes, and their regulation by glucocorticoids in nephrotic syndrome may aid in tailoring steroid treatment to the patient, by serving as prognostic biomarkers of disease activity. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42 List word counts below (do not paste the text here). Please see the Decision Letter Attachment for allowances as they pertain to your manuscript type. We apologise that this was unclear. Because we hypothesized that there is a qualitative difference between early and late responders, we determined clinical GC-sensitivity/resistance by the initial response to prednisolone treatment at 2 weeks, which is earlier than the common definition (a recent report showing prognositic value of the early response -at 7d -supports this early definition; Vivarelli et al. 2010 J Pediatr.). Newly diagnosed patients were treated with 2mg/kg prednisolone for 4 weeks, according to the ISKDC protocol. According to our regional protocol, frequent relapsing nephrotic syndrome patients were treated with 1 mg/kg prednisolone at relapse, with the intention of reducing steroid toxicity. The text in Cases and Methods has been amended to make this clear.
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2. In table 1; patients number 6 and 7 were considered glucocorticoid resistant although their urinary protein to creatinine ratios after 4 weeks of therapy were below 0.2 which is the normal value (0.03 and 0.18 respectively) and thus these 2 patients are steroid sensitive. Please clarify.
As mentioned above, we determined clinical GC-sensitivity/resistance at 2 weeks. We classified GC-sensitive patients as those who showed complete resolution of proteinuria (urine protein/creatinine ratio less than 0.2) at 2 weeks and also remained negative at 4 weeks. If proteinuria was present at 2 weeks, these patients were classified as GC-resistant. This has now been clarified in the Cases and Methods section. 4. In Figure 1 ; HSD11B1, HSD11B2 and NR3C1 expression levels should be illustrated and P values should be written either on the figure if applicable or in the results section.
We did consider this when presenting our data. However, the absolute levels of HSD11B1, HSD11B2 and NR3C1 mRNA were measured on different days, so variance between patients may reflect differences in assay conditions. However, samples from the same patient were always assayed together, so we have presented the results as the fold induction following dexamethasone treatment. This is now mentioned in the Results and Discussion section. P values have been added to the figure.
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Reviewer 2's comment 1. The authors did not identify inclusion and exclusion criteria for their subjects. Thus it is unclear if these are children with idiopathic nephrotic syndrome in whom they are studying. Further they did not specify the case definition by which they diagnosed these patients with All childhood NS patients admitted in our hospital for the duration of this study were included, with informed consent. The diagnosis of idiopathic nephrotic syndrome was made by pediatric nephrologists based on clinical and laboratory findings and this information is now included in the Cases and Methods section. 2. Regarding the subjects that they studied, they did not specify the ethnicity of their subjects. Presumably these patients are Japanese, but it is not specified. This is important because the underlying presumption is that the differences in steroid responsiveness is dictated by gene expression levels of HSD11B1 and HSD11B2. If this is the case, then there is a presumption that there is some type of gene variant responsible for the differences in gene expression, epigenetics, or gene-environment interaction. Thus, the underlying gene variants may or may not be present in other populations (which is important in considering the generalizability of the observation to other populations).
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Reviewer 2 is correct, all the patients were Japanese. This information has been added to the Cases and Methods section. We also added a comment on this as a study limitation in the Results and Discussion section, as suggested by the Reviewer.
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3. The medication dosing and clinical response of each case was not described so as to verify the degree of steroid resistance of the nonresponders.
Both Reviewers raised this important point. We apologise that this was unclear. For newly diagnosed patients, induction therapy was initiated with 2 mg/kg prednisolone for 4 weeks (60 mg/m 2 /day), according to the ISKDC protocol. Relapse patients were treated according to our regional protocol which states that if patients are not prescribed prednisolone before relapse, then to reduce steroid toxicity, initially 1 mg/kg prednisolone (maximum dose of 30 mg/m 2 /day) is administered, which is lower than the common protocol. Patients already undergoing treatment with ≥1 mg/kg prednisolone are started on 2 mg/kg prednisolone daily. For the infrequent relapse patient (patient 7), daily 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 prednisolone was administered at a dose of 2 mg/kg (60 mg/m 2 /day) until the proteinuria disappeared. The 3 frequently relapsing nephrotic syndrome patients were all treated with 1 mg/kg prednisolone therapy at relapse. We determined clinical GC-sensitivity/resistance by the initial response to prednisolone treatment at 2 weeks, which is earlier than the 4 weeks commonly used as we hypothesized that there is a qualitative difference between early and late responders, and because a recent report has shown the early response (at 7 days) is of prognostic in nephrotic syndrome patients. This information is now included in the Cases and Methods section. 4. In the results, the describe the testing of the mRNA levels for the above genes but do not report the statistics of their results, which one is to presume that they did not detect statistically significant difference in mRNA expression profiles between steroid responders and non-responders.
Data were analysed using the Wilcoxon matched pairs test. This is now mentioned in the Cases and Methods section and also the Figure legend . HSD11B2 mRNA levels were significantly increased by dexamethasone treatment of PBMC collected from GC-resistant NS patients both prior to, and following, their prednisolone therapy at 2 weeks. The text of Results and Discussion has been amended to clarify this point. 5. The write up of the conclusions could be stronger. For example they could have tried to discuss the significance of their findings in the context of the literature they made reference to in their introduction. Furthermore, a discussion of the strengths and weaknesses of the study would have also been appropriate.
We thank the Reviewer for these helpful suggestions. We have incorporated both comments on the significance of our study and discussed its limitations in the revised manuscript.
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